Open AccessPolyene and cytokine treatment of experimental aspergillosis
Author(s) -
Sionov Edward,
Segal Esther
Publication year - 2003
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/s0928-8244(03)00230-x
Subject(s) - aspergillosis , nystatin , amphotericin b , aspergillus fumigatus , cyclophosphamide , biology , mycosis , combination therapy , immunology , survival rate , cytokine , gastroenterology , medicine , microbiology and biotechnology , chemotherapy , antifungal , pharmacology
The aim of the present study was to assess the efficacy of amphotericin B (AMB), AMB‐intralipid admixture (AMB‐IL) or nystatin‐IL formulation (Ny‐IL) in combination with granulocyte colony stimulating factor (G‐CSF) in treatment of experimental murine aspergillosis. ICR mice were immunosuppressed by cyclophosphamide and 3 days later inoculated intravenously (i.v.) with Aspergillus fumigatus . Treatment was initiated 2 h later and administered for 5 consecutive days (polyenes, i.v.; G‐CSF, intraperitoneally). Combination therapy, particularly G‐CSF with AMB or AMB‐IL, significantly increased the survival rate (up to 87.3%) and prolonged the mean survival time (MST) (up to 28.8 days) in comparison to untreated controls (0% survival, MST 6.7 days) and to treatment with polyenes alone (up to 51.5% survival, MST 18.4 days). These data indicate that combination therapy could be beneficial for management of disseminated aspergillosis in humans.